Abstract
Acetylcysteine has been used to treat acetaminophen overdose for nearly 50 years. While no placebo controlled trials have been conducted, the efficacy of acetylcysteine is accepted for the prevention of hepatic injury when administered early after acetaminophen overdose. Acetylcysteine can be administered as an infusion or oral solution. The duration of treatment varies from 21 to 72 hours, depending on the protocol. Acetylcysteine also prevents death when administered to patients with hepatic failure from acetaminophen.
Keywords: Acetaminophen, acetylcysteine, hepatic failure, overdose, placebo, Acetaminophen poisoning, CYP2E1, Nacetyl-p-benzoquinoneimine (NAPQI), minor metabolic pathway, therapeutic dose, hepatic injury, antidotes, glutathione, hepatic injury.
Current Pharmaceutical Biotechnology
Title:Acetylcysteine Therapy for Acetaminophen Poisoning
Volume: 13 Issue: 10
Author(s): Kennon Heard and Jody Green
Affiliation:
Keywords: Acetaminophen, acetylcysteine, hepatic failure, overdose, placebo, Acetaminophen poisoning, CYP2E1, Nacetyl-p-benzoquinoneimine (NAPQI), minor metabolic pathway, therapeutic dose, hepatic injury, antidotes, glutathione, hepatic injury.
Abstract: Acetylcysteine has been used to treat acetaminophen overdose for nearly 50 years. While no placebo controlled trials have been conducted, the efficacy of acetylcysteine is accepted for the prevention of hepatic injury when administered early after acetaminophen overdose. Acetylcysteine can be administered as an infusion or oral solution. The duration of treatment varies from 21 to 72 hours, depending on the protocol. Acetylcysteine also prevents death when administered to patients with hepatic failure from acetaminophen.
Export Options
About this article
Cite this article as:
Heard Kennon and Green Jody, Acetylcysteine Therapy for Acetaminophen Poisoning, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273146
DOI https://dx.doi.org/10.2174/138920112802273146 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: An Update
Current Respiratory Medicine Reviews Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease
Current Drug Targets Central Nervous System Agents Used as Trypanosoma cruzi Infection Chemotherapy: Phenothiazines and Related Compounds
Current Medicinal Chemistry - Anti-Infective Agents Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Improving Adherence to Antipsychotic Pharmacotherapy
Current Clinical Pharmacology An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Current Cancer Drug Targets Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Metabolic Profile of Flunitrazepam: Clinical and Forensic Toxicological Aspects
Drug Metabolism Letters Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life
Current Diabetes Reviews Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis
Current Reviews in Clinical and Experimental Pharmacology Role of Infrared Spectroscopy in Medicinal Plants Research in Pakistan
Current Bioactive Compounds Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets